This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lars Farde, MD; Gíran Sedvall, MD; Frits-Axel Wiesel, MD; Hakan Hall, PhD; Christer Halldin, PhD; Sharon Stone-Elander, PhD
Department of Psychiatry and Psychology Karolinska Institute S-104 01 Stockholm Sweden

Arch Gen Psychiatry. 1988;45(6):599-600.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply—

Seeman argues, somewhat vaguely, that "the analytical method determining the control values can have considerable influence on whether abnormal values may be detected." He refers to the early PET finding by Wong et al¹ that no D₂ dopamine receptor abnormalities were found in drug-naive schizophrenics and to the more recent report where the same group, using a more sophisticated quantitative method, demonstrated a twofold to threefold elevation of D₂ dopamine receptor densities in the caudate nucleus.² Using a different quantitative method and a different ligand, we could not confirm the occurrence of substantially elevated D₂ dopamine receptor densities in the putamen or the caudate nucleus of drug-naive schizophrenics.

The PET determinations of receptor characteristics in vivo are based on a number of measured variables influenced by a number of biologic functions. There are several major differences between the PET methodologies used by Wong et al . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?